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Abstract 34 
Background 35 
Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by 36 
mutations in the α-galactosidase A (GLA) gene causing deficiency of α-galactosidase 37 
A which results in progressive glycosphingolipid accumulation, especially 38 
globotriaosylceramide (Gb3), in body liquids and lysosomes. In a large cohort of FD 39 
patients, we aimed to establish genotype/phenotype relations as indicated by serum 40 
LysoGb3 (deacylated Gb3). 41 
Methods 42 
In 69 consecutive adult FD patients (males: n=28 (41%)) with a GLA-mutation 43 
confirmed diagnosis, we conducted a multidisciplinary clinical characterization during 44 
their routine annual examinations, and measured serum LysoGb3 levels by high-45 
sensitive electrospray ionization liquid chromatography tandem mass spectrometry.  46 
Results 47 
Serum levels of LysoGb3 were significantly higher in Classic compared with Later-48 
Onset phenotype and higher in the latter compared with controls, both in males (52 49 
[40-83] vs 9.5 [4.5-20] vs 0.47 [0.41-0.61]ng/ml, P<0.001) and in females (9.9 [7.9-50 
14] vs 4.9 [1.6-4.9] vs 0.41 [0.33-0.48]ng/ml, P<0.001), respectively. Multivariate 51 
linear regression analysis showed that LysoGb3 levels were independently 52 
associated with, serum creatinine (β=0.09, 95%CI 0.04-0.13, P<0.001) and the 53 
presence of cardiomyopathy (β=25, 95%CI 9.8-41, P=0.002). LysoGb3 levels were 54 
higher in males with frame-shift and nonsense mutations than in males with missense 55 
mutations (84 [72-109] vs 41 [37-52]ng/ml, P=0.002). 56 
Conclusion 57 
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LysoGb3 relates to disease severity, enzyme replacement response, and to the 58 
genotype severity in males. LysoGb3 supports identifying patients at risk who require 59 
intensive monitoring and treatment. LysoGb3 appears to be one marker of metabolic 60 
phenotyping of FD. 61 
 62 
 63 
Keywords: Fabry disease; GLA-mutation; LysoGb3; biomarker; genotype phenotype 64 
relation; disease severity.  65 
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1. Introduction 66 
 67 
Fabry disease (FD) (OMIM#301500) is an X-linked disease, resulting from the 68 
deficient activity of the lysosomal enzyme α-galactosidase A (α-Gal A) [1, 2]. The 69 
enzymatic defect causes the progressive accumulation of globotriaosylceramide 70 
(Gb3) and related glycosphingolipids in the plasma and in tissue lysosomes 71 
throughout the body [1]. 72 
There are two major phenotypes, Classic and Later-Onset [1, 3-6]. The Classic 73 
phenotype is more severe due to very low or absent α-Gal A activity, with the typical 74 
early symptoms such as acroparesthesias, angiokeratoma, corneal opacities and 75 
hypohidrosis, particularly in males. With advancing age, the progressive deposition of 76 
glycosphingolipids lead to cardiomyopathy, deterioration of kidney function, and 77 
premature strokes [7, 8]. The Later-Onset phenotype is typically less severe with a 78 
significant residual α-Gal A activity in males, who usually lack the early symptoms but 79 
present with a cardiomyopathy or chronic kidney disease in the adult age [3, 9-11]. 80 
The phenotypic heterogeneity can delay the correct diagnosis.  In females, α-Gal A 81 
activity can be normal due to random X-chromosomal inactivation [12]. Even genetic 82 
testing can result in novel GLA variants with unknown clinical significance [13]. This 83 
raises questions with regard to disease onset and progression, particularly in 84 
asymptomatic patients identified in family screening.  85 
Recently, enhanced deposits of globotriaosylsphingosine (LysoGb3) have been 86 
shown to be a characteristic feature of FD [14]. The deacylated Gb3, LysoGb3 (also 87 
called LysoGl3), also known as globotriaosylsphingosine, has been reported as a 88 
potential diagnostic tool in both classic and uncertain cases [15]. The utility of 89 
LysoGb3 is still controversial, as discussed in previous studies [15, 16], due to 90 
concerns that LysoGb3 levels may not be strongly associated with disease 91 
phenotype [17].  To answer these concerns, we evaluated whether a 92 
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genotype/phenotype association can be established using serum LysoGb3 levels. To 93 
this end, we analyzed a clinical, biochemical and genetic characterization of a large 94 
FD patient’s cohort that was regularly monitored at a single FD center. This is the first 95 
study to associate LysoGb3 levels with the FD-related comorbidities and the 96 
genotype severity.  97 
  98 
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2. Methods 99 
2.1. Study participants and clinical work-up 100 
The study was conducted in accordance with the principles of the Helsinki 101 
Declaration. Informed consent for collecting clinical data and blood samples for 102 
biobanking was obtained from all patients. 103 
We recruited 69 consecutive adult patients (males: n=28 (41%)) at the University 104 
Hospital Zurich, Switzerland, between January 2014 and December 2016. All 105 
patients had a confirmed GLA-mutation diagnosis and presented for routine annual 106 
examinations at our FD center. The cohort was established in 2001 when ERT was 107 
approved and offered to FD patients. ERT was prescribed at the licensed dose of 108 
either 0.2 mg/kg body weight of recombinant agalsidase- (Replagal) or 1 mg/kg 109 
body weight agalsidase- (Fabrazyme) and given intravenously every 14 days. 110 
All patients had a comprehensive workup, including medical history, cardiac, renal, 111 
and neurological evaluations.  The occurrence of stroke or TIA (transient ischemic 112 
attack) was evaluated during annual examinations by asking the patient and/or using 113 
the medical records. Standard transthoracic 2D-echocardiography was routinely 114 
performed in all patients. LVMMI was calculated using the Devereux formula [18]. 115 
Cardiomyopathy was defined as the presence of diastolic dysfunction and/or left 116 
ventricular hypertrophy on echocardiography or heart MRI. 117 
For the present analyses, all clinical and routine laboratory results were obtained 118 
from the patients` medical records.  119 
The healthy group consisted of 13 females and 13 males aged between 17 and 69 120 
years. 121 
 122 
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2.2. Phenotyping 123 
The phenotyping was performed blinded to the LysoGb3 levels and as reported 124 
previously [5, 19].  The phenotype was classified based on the genotype. Nonsense, 125 
frameshift, consensus splice site and certain missense mutations encode for 0 to 1% 126 
residual α-Gal activity and cause Classic phenotype in males. Alternative splicing 127 
mutations and certain other missense mutations encode for more than 1% of normal 128 
α-Gal activity and cause Later-Onset phenotype in males. The phenotype was 129 
confirmed based on the age of symptoms onset for each mutation. For novel 130 
missense mutations, the phenotype was classified based on clinical symptoms and 131 
signs in males and by in vitro expression assays [4, 20]. 132 
 133 
2.3. LysoGb3 measurement 134 
For serum LysoGb3 levels, blood samples were centrifuged and serum was 135 
immediately frozen at −80°C for a later batch analysis. The samples were measured 136 
by high-sensitive electrospray ionization liquid chromatography tandem mass 137 
spectrometry (ESI LC-MS/MS) using an adapted method from Gold [21]. A 7-point 138 
serum calibrator and an internal standard for LysoGb3 quantification (covering the 139 
analytic range from 0-120 ng/mL; lower limit of quantification: 0.3 ng/mL), and three 140 
level controls (3, 30 and 100 ng/mL) for quality control were used (ARCHIMED Life 141 
Science GmbH, Vienna, Austria; www.archimedlife.com). Further experimental 142 
details on mass spectrometric conditions and sample work-up will be available upon 143 
request.  144 
 145 
2.4. Statistical analysis 146 
We used descriptive statistics for the baseline characteristics and laboratory 147 
parameters. Categorical variables were expressed as proportions, continuous 148 
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variables as means with standard deviations and medians with interquartile ranges 149 
(IQR). Normal distribution was assessed by Kolmogorov-Smirnov-Test. Comparisons 150 
between the study groups were performed using the t test, Mann–Whitney U test, the 151 
Chi-square or one-way analysis of variance (ANOVA) test as appropriate. 152 
Correlations were determined according to the method of Spearman. 153 
Receiver operating characteristics (ROC) procedure was used to predict the Classic 154 
phenotype by serum LysoGb3 levels in all FD males and females. ROC was also 155 
used to predict FD among FD patients and controls. 156 
Univariate linear regression analysis was applied to assess the association between 157 
serum levels of LysoGb3 and sex, phenotype as well as disease activity as reflected 158 
by the FD-related clinical work-up parameters. Multivariate linear regression model 159 
was used to evaluate which of these disease activity parameters are independently 160 
associated with the LysoGb3 levels after adjustment for sex and phenotype.  161 
Statistical analyses were performed using SPSS/PC (version 22.0; SPSS Inc., 162 
Chicago, IL, USA) software package. A statistical significance level of 0.05 was used. 163 
All hypothesis testing was two-tailed.  164 
 165 
  166 
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3. Results 167 
3.1. Baseline characteristics 168 
The baseline characteristics and sex of all patients are presented in Table 1. In male 169 
patients, serum creatinine levels were higher and cardiomyopathy more frequent than 170 
in female patients. All patients on renal replacement therapy were male.  171 
 172 
  173 
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Table 1. Baseline characteristics 174 
 175 
 All patients 
N=69 
Males 
N=28 
Females 
N=41 
P-value 
Age, years 40 [31-53] 43 [35-51] 37 [30-56] 0.62 
Phenotype n (%)    0.31 
Classic   61 (88) 23 (82) 38 (93)  
Later-Onset  9 (12) 5 (18) 4 (7)  
On ERT n (%) 52 (75) 25 (89) 27 (64) 0.02 
Serum creatinine, 
µmol/L 
123 ± 175 198 ± 258 72 ± 29 0.003 
Urine protein/creatinine 
ratio mmol/L ** 
0.06 ± 0.19 0.05 ± 0.07 0.06 ± 0.23 0.94 
On dialysis n (%) 3 (3) 3 (11) 0 (0) 0.03 
Kidney transplant n (%) 5 (7) 5 (18) 0 (0) 0.005 
Cardiomyopathy n (%) 33 (48) 18 (64) 15 (37) 0.02 
LVMMI, g/m2 103 ± 55  125 ± 62 88 ± 44 0.007 
Stroke/TIA n (%) 10 (14) 4 (14) 6 (15) 1.00 
 176 
* estimated according to the CKD-Epi formula 177 
** Patients on renal replacement excluded 178 
 179 
Plus-minus values are means ± SD. Numbers with ranges in square brackets are 180 
medians and interquartile ranges. 181 
 182 
Abbreviations: ERT, Enzyme Replacement Therapy; MSSI, Mainz Severity Score 183 
Index, LVMMI, Left Ventricular Mass Index; TIA, Transient Ischemic Attack.  184 
 185 
 186 
  187 
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3.2. LysoGb3 in relation to sex and phenotype 188 
In males and females, serum levels of LysoGb3 were significantly higher in Classic 189 
than in Later-Onset phenotype patients. In healthy controls, LysoGb3 levels were 190 
lower than in FD patients (Figure 1A and 1B).  191 
 192 
  193 
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Figure 1. Serum levels of LysoGb3 in males (A) and females (B) depending of 194 
phenotype and in comparison to healthy controls*. 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
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Table legend to Figure 1A. 208 
 209 
Classic Males    
Age GLA Mutation Predicted Enzyme Protein Change  
Cumulative Dose 
Agalsidase-α, mg  
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
27 c.559_560delAT p.M187Vfs*6 
 
 
148.02 
29 c.1147_1149del p.F383del 
 
 
117.95 
50 Deletion exon 2  3591.20  115.00 
18 c.744_745delTA p.F248LfsX7 
 
6580.00 95.50 
44 c.744_745delTA p.F248LfsX8 1935.20 2124.00 92.20 
55 c.899T>A  p.L300H 1988.00 16614.00 83.00 
49 c.744_745delTA p.F248LfsX8 2407.20 408.00 74.80 
31 c.1055_1057dupCTA p.A352_M353insT 963.60  71.70 
44 c.370-2A>G Cons. Splice Site 3539.20  57.60 
30 c.679C>T p.R220X 1240.00 17236.00 57.52 
59 c.1033T>C p.S345P 5088.00  55.20 
61 c.1033T>C p.S345P 4089.60  52.31 
67 c.581C>T p.T194I 4316.80  46.10 
39 c.827G>A p.S276N 3312.00  45.60 
44 c.581C>T p.T194I 3164.00  41.00 
36 c.581C>T p.T194I 4121.60  40.40 
59 c.899T>A  p.L300H 864.00 13536.00 40.10 
51 c.581C>T p.T194I 3778.80  40.00 
23 c.125T>C p.M42T 1776.00  39.00 
40 c.370-2A>G Cons. Splice Site 3175.20  36.80 
35 c.125T>C p.M42T 3192.00  35.30 
39 c.1033T>C p.S345P 2148.80 10472.00 24.70 
47 c.613C>T p.Pro205Ser 3608.00  17.20 
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Later-Onset Males 
Age GLA Mutation Predicted Enzyme Protein Change  
Cumulative Dose 
Agalsidase-α, mg 
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
39 c.902G>A p.R301Q   34.30 
41 c.337T>C p.F113L 
 
1456.00 15.40 
65 c.902G>A p.R301Q 2275.20 17064.00 11.50 
44 c.902G>A p.R301Q 1776.00 8288.00 7.50 
63 c.644A>G p.N215S 1008.00  5.30 
41 c.1196G>C p.W399S 
 
 
2.00 
15 
 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
Numbers with ranges in square brackets are medians and interquartile ranges217 
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Table legend to Figure 1B. 218 
 
Classic Heterozygotes 
  
Age GLA Mutation Predicted Enzyme Protein Change  
Cumulative Dose 
Agalsidase-α, mg 
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
68 c.581C>T p.T194I 3328.00  26.81 
35 c.1167dupT p.V390CfsX9   23.56 
48 c.365delA p.N122IfsX8 2049.60   
65 c.581C>T p.T194I 3476.00  17.80 
51 c.1033T>C p.S345P 1364.00  16.50 
68 c.1033T>C p.S345P 1531.20  16.10 
55 c.796G>T p.D266T  2100  
65 c.640-3C>G Cons. Splice Site 5149.6  14.44 
28 c.1033T>C p.S345P 907.20  13.60 
48 c.72G>A p.Y24X   13.50 
36 c.1235_1236delCT p.N122IfsX8 194.40  12.60 
63 c.581C>T p.T194I 3113.60  12.00 
35 c.901C>T p.R301X 79.20  10.70 
31 c.1055_1057dupCTA p.A352_M353insT   10.60 
25 c.1147_1149del p.F383del   10.10 
39 c.581C>T p.T194I   10.10 
17 c.1167dupT p.V390CfsX9 1356.80  10.10 
41 c.640-3C>G Cons. Splice Site 4238.00  10.00 
51 c.1167dupT p.V390CfsX9 1298.00  9.85 
37 c.581C>T p.T194I   9.70 
63 c.72G>A p.Y24X 3245.20  9.30 
56 c.796G>T p.D266T  2024.00 8.90 
62 c.744_745delTA p.F248LfsX7   8.60 
23 c.125T>C p.M42T 2360.00  8.60 
17 
 
34 c.581C>T p.T194I 3366.00  8.30 
29 c.704C>A p.Ser235Tyr 
 
 
8.2 
31 c.125T>C p.M42T 2419.20  8.00 
33 c.744_745delTA p.F248LfsX7 379.60  7.90 
42 c.1033T>C p.S345P 
 
 
7.80 
24 c.1167dupT p.V390CfsX9 1560.00  7.61 
29 c.125T>C p.M42T 1786.00  7.5 
26 c.125T>C p.M42T 2195.20  7.30 
23 c.1033T>C p.S345P   7.00 
32 c.581C>T p.T194I 
 
 
6.10 
36 c.154T>C p.C52R 
  
 
5.90 
39 c.744_745delTA p.F248LfsX7 775.20 5928.00 5.20 
48 c.870G>C p.M290I 
 
  
.80 
 
Later-Onset Heterozygotes 
   
Age GLA Mutation Predicted Enzyme Protein Change  
Cumulative Dose 
Agalsidase-α, mg 
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
37 c.902G>A p.R301Q 
 
 
5.20 
73 c.902G>A p.R301Q 2128.00  4.90 
33 c.337T>C p.F113L 
 
 
1.6 
 219 
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There was one overlap in LysoGb3 levels between males with the Classic and Later-220 
Onset phenotypes: the male with the highest LysoGb3 level within the Later-Onset 221 
phenotype group was newly diagnosed having FD and not yet on ERT. Among the 222 
females, one Classic and three Later-Onset had similar LysoGb3 values. There was 223 
no overlap in LysoGb3 levels between FD patients and controls.  224 
The ROC curve indicated a high predictive value for LysoGb3 to identify FD patients 225 
among patients and controls: AUC=1 for each sex, with the best calculated cutoff for 226 
sensitivity and specificity at 34.8 ng/ml for males and 8.1 ng/ml for females.  227 
For prediction of the Classic versus Later-Onset phenotype among FD patients, 228 
LysoGb3 levels nearly ideally predicted the Classic phenotype in males: AUC=0.98 229 
(best calculated cutoff 43.3 ng/ml); in females, the predictive accuracy of LysoGb3 230 
levels was high:  AUC=0.81 (best calculated cutoff 9.9 ng/ml). 231 
 232 
3.3. LysoGb3 in relation to disease severity 233 
In an univariate linear regression analysis, LysoGb3 levels were associated with sex, 234 
phenotype, serum creatinine, renal replacement, LVMMI, presence of 235 
cardiomyopathy and stroke/TIA. In a multivariate linear regression analysis, if 236 
adjusted for sex and phenotype, LysoGb3 levels remained independently associated 237 
with the same parameters (Table 2).238 
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Table 2. Linear regression for serum LysoGb3 as the dependent variable. 239 
 240 
 Univariate Multivariate * 
Characteristics β (95% CI)  P Value β (95% CI)  P Value 
Sex, male 52.3 (44.2-62.4)  <0.001 n.a.  
Classic phenotype 30.6 (22.7-38.5)  <0.001 n.a.  
Age, year  0.58 (0.40-0.75)  <0.001 1.01 (0.64-1.38) <0.001 
Serum creatinine, µmol/L 0.11 (0.07-0.15)  <0.001 0.09 (0.04-0.13) <0.001 
Urin protein/creatinine ratio, mmol/L 46.8 (-4.3 to 97.8)  0.07   
Renal replacement 45.4 (21.7-69.0)  <0.001 42.2 (18.9-65.5) 0.001 
Cardiomyopathy 32.1 (19.8-44.5)  <0.001 25.5 (9.81-41.1) 0.002 
LVMMI, g/m2 0.24 (0.18-0.30)  <0.001 0.29 (0.20-0.39) <0.001 
Stroke/TIA 27.6 (5.53-49.6)  0.02 23.0 (0.93-45.1) 0.04 
 241 
*Adjusted for sex and phenotype 242 
Abbreviations: LVMMI, left-ventricular myocardial index; TIA, trans ischemic attack. 243 
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LysoGb3 levels significantly correlated with the serum creatinine (R=0.28, P=0.02), 244 
LVMMI (R=0.27, P=0.03) and protein/creatinine ratio (R=0.33, P=0.007). LysoGb3 245 
levels weekly correlated with age in females (R=0.34, R=0.03) but not in males (R=-246 
0.22, P=0.26).  247 
 248 
3.4. LysoGb3 in relation to genotype and between family members 249 
If LysoGb3 measured during the routine annual examination was available in at least 250 
3 family members, the levels were grouped by the family, as shown in Figure 2. 251 
Within one family, the LysoGb3 levels were mostly similar among males and females 252 
respectively and were always higher in males than in females. If LysoGb3 showed 253 
greater differences between the family members with the same sex, it could be partly 254 
associated with differences in the disease burden and whether the patient was 255 
treated with enzyme replacement. In detail, in Family 1, the 44-year-old male with 256 
LysoGb3 of 92.2 ng/ml much earlier developed end-stage renal disease and required 257 
kidney transplantation than did his 49-year-old brother who had LysoGb3 of 74.8 258 
ng/ml. The relatively high LysoGb3 level of 95.5 ng/ml of their 18-year-old 259 
oligosymptomatic nephew remains difficult to interpret; the phenomenon of high 260 
LysoGb3 levels in children and younger adults is known from the literature [22] and 261 
may represent an early plateau during the pre-symptomatic period, this storage 262 
already begins during the fetal phase [23].  In Family 2, the 68-year-old female with 263 
the highest LysoGb3 level of 26.8 ng/ml has the most severe phenotype among the 264 
females within the same family being hemiplegic due to recurrent strokes despite 265 
ERT. In Family 4, the 35-year-old female had a higher LysoGb3 level (23.6 ng/ml) 266 
than had her aunt and cousin which might be explained by the fact that she was not 267 
yet on ERT due to compliance reasons. Previous studies showed that LysoGb3 268 
decreases following ERT initiation [24]. In Family 5, the 39-year-old male with the 269 
21 
 
lowest LysoGb3 level of 24.7 ng/ml has a less severe phenotype with normal kidney 270 
function and a lower MSSI than his 59 and 61-year-old uncles who had LysoGb3 271 
values of 55.2 and 52.3 ng/ml and are both on renal replacement therapy.    272 
  273 
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Figure 2. Plasma LysoGb3 levels per family*. 274 
 275 
 276 
 277 
 278 
 279 
* Families with at least three family members were plotted 280 
 281 
 282 
  283 
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** Table legend to Figure 2. 284 
 285 
Nr GLA Mutation / Predicted 
Enzyme Protein Change 
Phenotype LysoGb3 Sex Age ERT 
1 c.559_560delAT / 
p.M187Vfs*6 
(6 family members) 
Classic 95.5 m 18 + 
92.2 m 44 + 
74.8 m 49 + 
8.6 f 62 - 
7.9 f 20 + 
5.2 f 39 + 
2 c.581C>T / p.T194I 
(11 family members) 
Classic 46.1 m 67 + 
41.0 m 44 + 
40.4 m 36 + 
40.0 m 51 + 
26.8 f 68 + 
17.8 f 65 + 
12.0 f 63 + 
10.1 f 39 - 
9.7 f 37 - 
8.3 f 34 + 
6.1 f 32 - 
3 c.125T>C / p.M42T 
(6 family members) 
 
 
Classic 39.0 m 23 + 
35.3 m 35 + 
8.6 f 25 + 
7.5 f 29 + 
7.3 f 26 + 
8.0 f 31 + 
4 c.1167dupT / p.V390CfsX9 
(4 family members) 
 
 
Classic 23.6 f 35 - 
10.1 f 17 + 
9.9 f 51 + 
7.6 f 24 + 
5 c.1033T>C / p.S345P 
(8 family members) 
 
 
Classic 55.2 m 59 + 
52.3 m 61 + 
24.7 m 39 + 
16.5 f 51 + 
16.1 f 68 + 
13.6 f 28 + 
7.8 f 42 - 
7.0 f 23 - 
6 c.370-2A>G / Cons. Splice Classic 57.6 m 44 + 
24 
 
Site 
(3 family members) 
 
36.8 m 40 + 
14.4 f 65 + 
7 c.902G>A / p.R301Q 
(3 family members) 
 
Later-Onset 11.5 m 65 + 
5.2 f 37 - 
4.9 f 73 + 
 286 
Abbreviations: ERT, Enzyme Replacement Therapy. 287 
 288 
  289 
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The mutations within the Classic phenotype patients were subdivided into two groups 290 
according to their structure and function. Group A was defined by frame-shift or 291 
nonsense mutations that lead to a major change in the gene products which can be 292 
caused by deletions, insertions, duplications and some point mutations [1]. Group B 293 
included missense mutations caused by individual point mutations that lead to single 294 
amino acid changes.  Only patients with the same ERT preparation (α-agalsidase) 295 
with treatment duration of at least 5 years at stable dose were included into this 296 
analysis in order to balance the ERT effect on the LysoGb3 levels [24]. In males, 297 
LysoGb3 levels were higher in group A than in group B (Figure 3). In contrast, in 298 
females, LysoGb3 levels did not differ significantly between group A (n= 6) and group 299 
B (n=13) (10.0 [8.3-15.2] vs 12.0 [8.2-16.3]; P=0.77). 300 
  301 
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Figure 3. Serum Lysob3 levels in affected males* according to mutation severity by 302 
structure and function: A frame-shift and nonsense-mutation versus B missense 303 
mutations. 304 
  305 
Mutations
Ly
so
G
b3
, 
n
g/
m
l
A B
0
50
100
150
P=0.002
84 [72-109]
41 [37-52]
 306 
 307 
 308 
 309 
 310 
 311 
 312 
*Included only males with the same ERT preparation (α-agalsidase) at a stable dose 313 
of at least 5 years. 314 
315 
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Table legend to Figure 3.  316 
 317 
Mutations A  Mutations B 
GLA Mutation Predicted Aminoacid  Serum Lyso-
Gb3 (ng/ml) 
GLA 
Mutation 
Predicted Aminoacid Serum Lyso-
Gb3 (ng/ml) 
Deletion exon 2  115.0 c.125T>C p.M42T 39.0 
c.744_745delTA p.F248LfsX7 92.2 c.125T>C p.M42T 35.3 
c.744_745delTA p.F248LfsX7 74.8 c.581C>T p.T194I 41.0 
c.1055_1057dupCTA p.A352_M353insT 71.7 c.581C>T p.T194I 46.1 
  
 
c.581C>T p.T194I 40.0 
  
 c.581C>T p.T194I 
 
40.4  
  
 
c.899T>A 
 
p.L300H 
 
40.1 
 
 
c.899T>A p.L300H 83.0 
 
 
c.370-2A>G Cons. Splice Site 36.8 
 
 
c.370-2A>G Cons. Splice Site 57.6 
 
 
c.827G>A 
 
p.S276N 
 
45.6 
 
 
c.1033T>C p.S345P 52.3 
 
 
c.1033T>C 
 
p.S345P 
 
24.7 
 
 
c.1033T>C p.S345P 55.2 
 
 
c.613C>T 
 
p.P205S 
 
17.2 
  318 
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Discussion 319 
In this relatively large and well characterized cohort of genetically proven FD patients,  320 
serum levels of LysoGb3 were significantly higher than in the healthy controls. More 321 
importantly, LysoGb3 levels were significantly higher in the Classic than in the Later-322 
Onset phenotype in male and female patients. After adjustment for sex and 323 
phenotype, LysoGb3 was independently associated with the relevant co-morbidities 324 
such as kidney function, renal replacement therapy, cardiomyopathy, stroke and TIA.  325 
Within families, LysoGb3 levels were generally similar within one sex but always 326 
higher in males than in females. However, higher LysoGb3 levels in family members 327 
of the same sex were found in patients with higher disease activity, not on ERT, or at 328 
young age.  329 
Interestingly, the analysis of just the Classic phenotype, showed that serum LysoGb3 330 
levels were higher among the males with severe mutations, such as frame-shift or 331 
nonsense mutations, that are known to lead to grossly altered gene products. These 332 
high LysoGb3 levels may be partly interpreted as a result of particularly low or absent 333 
α-Gal A activities in males with such mutations resulting in accumulation of LysoGb3 334 
[25]. Additionally, LysoGb3 could be de-novo synthesized by sequential glycosylation 335 
of sphingoid bases by the action of a specific enzyme, more accelerated in males 336 
with “severe” mutations.  337 
In contrast to LysoGb3 levels in the male patients, LysoGb3 levels of female patients 338 
did not depend on the mutation severity which might be ascribed to the random X-339 
chromosomal inactivation in the heterozygous [12].  340 
In FD, the correct risk stratification based on an understanding of the genotype and 341 
phenotype relationship is an urgent though unmet clinical need. Since FD has 342 
become treatable with ERT [2, 26] and more recently with further treatment strategies 343 
[27-30], there is increasing awareness of FD among primary care physicians and 344 
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different specialists, and systematic screening among high-risk populations [31-33] 345 
and newborns [34] has become more frequent. This has resulted in increased 346 
detection of mutations with unknown clinical relevance [35, 36].  347 
The diagnosis is further complicated in females; at least 40% of the GLA-mutation 348 
confirmed females have normal or slightly decreased α-Gal A activities and require 349 
GLA sequencing to confirm heterozygosity [12, 37].  In males, the diagnosis of FD 350 
requires demonstrating of decreased α-Gal A activity in leucocytes; the diagnosis 351 
then can be confirmed by additional GLA mutation analysis. However, males with the 352 
Later-Onset phenotype may still have a significant residual enzyme activity. 353 
Consequently, male Later-Onset phenotype FD patients often lack the typical early-354 
onset classical manifestations, but they do show later disease manifestation and a 355 
predominance of single organ disease, particularly of the heart and kidney [3, 4, 9-356 
11]. In these patients, FD might not be recognized as the cause of heart, kidney, or 357 
cerebrovascular diseases. These might be misdiagnosed and ascribed to more 358 
common pathology including aging processes or cardiovascular risk factors [38].  359 
A highly sensitive and specific biomarker could fill the diagnostic gap and help avoid 360 
invasive biopsies and assure a swift diagnosis in patients with suspected FD. Such a 361 
biomarker may also improve disease staging and risk stratification as well as support 362 
the decision whether a patient should be started on ERT or should only be closely 363 
monitored.  364 
Previous studies identified LysoGb3 as a helpful diagnostic tool in classic and 365 
uncertain cases [14], and particularly in females [5].  Rombach and colleagues found 366 
LysoGb3 levels to be associated with white matter lesions in males, and with MSSI 367 
and left- ventricular mass in females [39]. Lenders and colleagues reported 368 
associations of LysoGb3 levels with the serum-mediated ERT inhibition [40].  369 
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In Later-Onset (so-called Non-classical) phenotype FD patients, Smid observed that 370 
LysoGb3 levels are similar in patients of the same sex and with the same GLA 371 
variant [16]. Our findings confirm the relation between LysoGb3 levels and Classic 372 
and Later-Onset phenotypes [16]. Moreover, our results show an independent 373 
association of LysoGb3 with the most important clinical manifestations such as renal, 374 
cardiac and cerebrovascular disease, and treatment response expressed by serum-375 
mediated ERT inhibition. Notably, our results did not show an influence of the long-376 
term cumulative dose of ERT on the LysoGb3 levels. This finding is in accordance 377 
with previous studies showing that LysoGb3 levels decrease after the ERT initiation 378 
and reach a plateau already after 2-3 months [24, 41]. 379 
Our study is the first to have analyzed LysoGb3 levels per family. It is valuable 380 
because family members usually have similar modifying genes and live under similar 381 
environmental conditions. Our data are also novel in showing a strong relation 382 
between LysoGb3 and mutation severity in males. The additional measurement of 383 
LysoGb3 may therefore augment the functional characterization of GLA mutations.         384 
However, previous studies [15, 16] show some overlap between LysoGb3 values of 385 
FD females and healthy individuals. While augmenting functional characterization of 386 
GLA mutations, LysoGb3 cannot replace a detailed clinical characterization using a 387 
multidisciplinary approach, family history, genetic testing and the phenotypic 388 
descriptions of the family mutation. Thus, more sensitive biomarkers will be needed 389 
to distinguish between the Later-Onset phenotype FD patients, particularly women, 390 
and healthy persons. 391 
LysoGb3 is not only a biomarker. It might also be involved in the FD pathology. 392 
LysoGb3 has been shown to promote Notch1-mediated inflammatory and fibrogenic 393 
response in podocytes potentially contributing to Fabry nephropathy [42]. LysoGb3 394 
treatment inhibited the proliferation and differentiation of fibroblasts into 395 
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myofibroblasts, reducing collagen synthesis and herewith compromising vascular 396 
remodeling [43]. It directly inhibited the α-Gal A activity and induced smooth muscle 397 
cell proliferation [14]. Administration of LysoGb3 stimulated the up-regulation of 398 
voltage-dependent Ca2+ channels in nociceptive neurons, suggesting that it may 399 
induce pain through direct actions on sensory neurons [44]. 400 
Several limitations merit consideration.  First, the number of our Later-Onset group 401 
patients was low. Second, the study was not designed to evaluate the ability of 402 
LysoGb3 to predict the development of major clinical events. Third, the study did not 403 
assess epigenetic phenomena, such as the influence of the degree of the random X-404 
chromosomal inactivation on LysoGb3 levels in females. Finally, for the use as a 405 
clinical biomarker, standardization of the technical methods and inter-laboratory 406 
testing is needed in order to compare LysoGb3 measurements among laboratories. 407 
In conclusion, the use of LysoGb3 as an additional laboratory biomarker appears to 408 
improve the detection and management of clinically relevant FD. LysoGb3 levels are 409 
associated with the important clinical sequelae of FD such as nephro-, 410 
cardiomyopathy and cerebrovascular disease, thus, LysoGb3 may represent the new 411 
concept of metabolic phenotype. LysoGb3 helps to stratify persons at risk and may 412 
provide guidance towards a more individualized treatment of patients. 413 
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